Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SCH 563705 is an effective and orally available CXCR2 and CXCR1 antagonist (IC50s: 1.3 nM, 7.3 nM and Kis of 1 and 3 nM, respectively).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 10-14 weeks | $ 2,270.00 | |
50 mg | 10-14 weeks | $ 2,980.00 | |
100 mg | 10-14 weeks | $ 4,000.00 |
Description | SCH 563705 is an effective and orally available CXCR2 and CXCR1 antagonist (IC50s: 1.3 nM, 7.3 nM and Kis of 1 and 3 nM, respectively). |
Targets&IC50 | CXCR2 (mouse):5.2 nM, CXCR1:3 nM (ki), CXCR1:7.3 nM, CXCR2:1 nM (ki), CXCR2:1.3 nM |
In vitro | SCH 563705 potently inhibits mouse CXCR2 (IC50 = 5.2 nM). SCH 563705 displays potent inhibition against both Gro-a and IL-8 induced human neutrophil migration (chemotaxis IC50 = 0.5 nM, against 30 nM of Gro-a; chemotaxis IC50 = 37 nM, against 3 nM of IL-8) [1][2]. |
In vivo | SCH 563705 has good oral pharmacokinetic profiles in rats, mice, monkeys, and dogs. SCH563705 (3-30 mg/kg p.o) treatment causes a dose-dependent elevation in plasma levels of CXCL1. SCH 563705 (50 mg/kg p.o) decreases blood Ly6G+ Ly6C+ neutrophil frequency and unchanged levels of Ly6GLy6Chi monocytes [1][2]. |
Molecular Weight | 425.48 |
Formula | C23H27N3O5 |
CAS No. | 473728-58-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL (70.51 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SCH 563705 473728-58-4 Autophagy GPCR/G Protein Immunology/Inflammation CXCR SCH-563705 SCH563705 inhibitor inhibit